Originally published on PharmacyTimes.com.
Michael Zeglinski, RPh, Senior Vice President of Specialty Pharmacy OptumRx, Chief Executive Officer at Avella and BriovaRx Specialty Pharmacies recently penned this article in Specialty Pharmacy Times about ways the health system can be optimized for patient care.
Thursday, August 23rd 2018 - Avella EVP of Clinical and Quality Assurance, Eric Sredzinski, was named a finalist for the Phoenix Business Journal Health Care Heroes Awards in the Non-Physician category.
As an executive vice president at Avella Specialty Pharmacy, Eric Sredzinski is responsible for the development and oversight of all clinical programs and services provided by Avella.
Avella EVP of Clinical and Quality Assurance, Eric Sredzinski, was recently quoted in the following Specialty Pharmacy Continuum article.
“While commercial and Medicare Part D patients are seeing rising cost-sharing requirements and greater demand for assistance, the increasing contributions from drug companies over the past five years seem to be plateauing,” Daniel Klein, the president and CEO of the Patient Access Network (PAN) Foundation, said during the Asembia 2018 Specialty Pharmacy Summit.
The following article was written by Avella's EVP of Clinical & Quality Assurance, Eric Sredzinski, and published in Specialty Pharmacy Times.
Oncology is already among the top therapeutic classes in specialty pharmacy.1 Experts say that drugs to fight cancer will continue to dominate the next wave of FDA approvals and enter the market at a rapid pace. Yet specifically how these medications are delivered to patients is also expected to evolve over time. This is especially true as manufacturers look to partner with specialty pharmacies that possess highly specific expertise in supporting patients with cancer and their complex treatment regimens.
The leading specialty pharmacy has compiled insights about the specialty drug pipeline along with an analysis of the network distribution strategies for these medications.
Phoenix, AZ -- Avella has just announced the release of a 16-page report detailing the specialty drug pipeline, including all of the latest medications expected to receive FDA approval within the coming months. The 2018 Q2 Specialty Medication Pipeline Report provides at-a-glance information about all of these therapies including indications, approval status, anticipated costs, clinical considerations and therapeutic alternatives, among other key data points. It also provides helpful explanations of the various designations and approval processes undertaken by the FDA for specific types of medication such as orphan drugs and breakthrough therapies.
NCPDP announced today the Opening Keynote Panel for its 2018 Annual Technology & Business Conference, Industry United to Improve the Patient Journey, May 7-9, 2018, at the Westin Kierland Resort & Spa in Scottsdale, Arizona. The Keynote Panel will address “Data Challenges and Opportunities to Improve the Patient Journey,” on Tuesday, May 8, 2018. Avella founder and chairman of the board, John Musil, will participate on the panel representing specialty pharmacy.
Many of today’s most effective specialty drugs are distributed through limited networks of specialty pharmacies, ranging in size from exclusive (one to two pharmacies) through limited small (two to five pharmacies) and limited large (six to 15 pharmacies). A new white paper from Avella Specialty Pharmacy reports that with 79.2% of manufacturers managing their specialty products through a limited distribution (LD) model, these LDs are shrinking even more, consisting of fewer pharmacies than they did just a decade ago.
If you haven’t already, we hope you’ll begin reading this 2-part series by viewing part 1, where we profile 5 women who we’ve identified among specialty pharmacy’s most highly-regarded leaders. In the conclusion to this series, you’ll meet another group of women who are applying their unique capabilities and expertise to positively impact their organizations, as well as the industry at large.
This article originally appeared on Drug Channels
Time for our annual review of the latest Inc. 5000 list, the magazine’s annual ranking of the fastest-growing private companies in the United States. The list offers a valuable snapshot of the dynamic specialty pharmacy industry. This marks our sixth annual review of the list.
We have identified 15 specialty pharmacies on the 2017 list, which is based upon revenue growth from 2013 to 2016. Annual revenues range from $6.4 million to $1.3 billion.